- Subscribe
- Premium
- C-Suite
- Insiders
- M&A
- Gurus
- Spinoffs
- Buybacks
- More
After a few years of writing these posts, I’ve come to realize there are three different types of Insider Weekends articles. The first is where an insider transaction immediately pops out to us as the clear winner to be featured in our post for the week. Those tend to be most of our articles, especially after we’re out of earning related quiet periods.
The second type most commonly happens during this quiet period, and it’s where we have to do quite a bit of digging to find a quality idea to feature – often having to go beyond the top five list of insider purchases and sales to find the right business. And the last type, which is my personal favorite, is when there’s an abundance of ideas because there’s something fascinating about each transaction we come across.
This week is one of those abundant weeks, so in traditional fashion when we write these kinds of articles, we decided to write a little bit about three different companies in our list of top five buys below. This week there’s actually another purchase outside our list of top five insider buys that we wanted to briefly cover as well.
Veradermics Inc. (MANE): $38.48
Market Cap: $1.44B
Enterprise Value: $1.53B
Veradermics is a late clinical-stage biopharmaceutical company focused on dermatology. The company’s lead candidate under evaluation, VDPHL01, has the potential to become the first non-hormonal oral therapeutic for hair regrowth in women and men. Veradermics has three separate studies each evaluating VDPHL01 in different patient populations, with all these trials and studies either in Phase 2 or Phase 3. Beyond VDPHL01, Veradermics does have some exploratory assets in alopecia areata (autoimmune disorder that causes patches of bald spots), common warts and molluscum contagiosum that may be advanced in the future but no progress has been made on those fronts as the company has chosen to prioritize and advance VDPHL01.